$PBIO makes CBD Oil Water Soluble. This Could Impact a $22B..
==============================
PBIO (Pressure Bio Sciences Inc.)
Current Price: $3.05
Investor Presentation
Chart Analysis
Website | Recent News
========================
Members,
We hope you are enjoying this long weekend, and much deserved time off.
As many of you know, we are coming off an amazing week of trading, which included over +182% in realistic gains.
One company that made a major contribution to that impressive gains totals was PBIO (Pressure Bio Sciences Inc.).
We first brought PBIO to your attention last Wednesday, and watched it deliver over +51% in realistic gains in just one trading session.
We continue to love the growth potential of this highly innovative company.
Based on our chart analysis and current market conditions, we still believe that PBIO has plenty of room to run from here, and should remain on the very top of your watchlist.
About Pressure BioSciences, Inc.
Pressure Bio Sciences, Inc. (PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Their products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or "PCT") hydro static pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydro static pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, bio molecule extraction). Their primary focus is in the development of high pressure-based products for bio marker and target discovery, drug design and development, bio therapeutics characterization and quality control, food science, soil & plant biology, forensics, and counter-bio terror applications. Additionally, PBIO is actively expanding the use of their pressure-based technologies in the following areas: (1) the use of their recently acquired technology from BaroFold, Inc. (the "Baro fold" technology) to allow entry into the biologics manufacturing and contract research services sector, and (2) the use of their recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology ("UST") platform to (i) create stable nano emulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
Investment Highlights
Seasoned Management Team & Board of Directors
Annual Revenue of $2.24M (FY2017)
Three Novel, Enabling, Patent Protected, Proprietary Pressure-based Platforms
Proven Core Technology (Over 300 PCT Systems Installed): Razor/Razor blade Business Model
Sales into the Research Market (fast market penetration with minimal approvals required)
Increasing Number of 3rd Party Publications from Marquee Laboratories
PCT Breaks Through Bottlenecks and Barriers to Enable and Accelerate Scientific Discovery
PreEMT Can Impact and Improve Protein Drug Therapeutics
UST Offers the Potential to Produce Highly Stable Nano emulsions, Including in the Food and CBD Markets
Significant Multi-Billion Dollar Market Opportunity (~500K Scientists in 80K Labs Worldwide)
Company Overview
Three Business Segments - Three Unique Technology Platforms
Research Products and Services (PCT Platform)
PCT: Pressure Cycling Technology (alternating cycles of high/low pressure to control biomolecules)
Focus: to improve the quality of biological sample preparation, one of the most crucial yet errorprone steps in all of scientific research, performed by tens of thousands of scientists worldwide in pharma, biotech, academia and government research laboratories.
15 Patents, 300 PCT Systems installed, 175+ customers, 120+ publications, 2017 revenue ($2.24M)
Biological Contract Services (PreEMT Platform)
PreEMT: Pressure Enabled Protein Manufacturing Technology
Focus: to improve the quality of protein therapeutics, accelerate therapeutic protein development, and manufacture follow-on biologics by employing high pressure for dis aggregation & controlled refolding of re combinant proteins into their native structures for desired drug activity.
8 Patents, Dec 2017 BaroFold Acquisition, Initial Contract Underway, Negotiating with Client #2
Nanoemulsion Manufacturing Services (UST Platform)
UST: Ultra Shear Technology (combines high hydro static pressure & intense shear forces)
Focus: to produce higher quality, more stable nano emulsions with improved absorption, higher bio availability, and lower surfactant levels: food, pharmaceuticals, nutra ceuticals, cosmetics, lubricants, paint, and cannabis oil extracts (water soluble CBD) compared to standard emulsions
Short-Term Growth Drivers
Research Products & Services PCT Platform):
New Next Generation Barocycler 2320EXTREME
Additions to Sales & Marketing Team (one to four field sales managers in 2018)
Novel Micro-Pestle Consumable…Potential Use in Pathology, etc.
Four Additional PCT-based Instruments to be Released over Next 12 Months
PBI Products Fill Existing Needs in $291B (2021 est.) Bio pharmaceutical Market
Biological Contract Services (PreEMT Platform): Consistent Revenue Stream fromServices to Protein Therapeutic Companies…plus the Potential for Millions of dollars from Royalties on Manufacturing Scale Licenses
Nano emulsion Manufacturing Services (UST Platform): Consistent Revenue Stream from Services to Food, Cosmetic, and Nutraceutical (CBD, CBG) Markets for Potential Development of Low Cost, Scalable Production of Nano emulsions…plus the Potential for Millions of dollars from Royalties on Manufacturing Scale Licenses
Recent Developments for PBIO
Pressure Bio Sciences Makes CBD Oil Water Soluble, Offering Solution to CBD Absorption Issue in Food & Beverages
Last week, the Company released a short video demonstrating the Company's proprietary Ultra Shear Technology (USTTM) platform and its ability to create extremely small, nanometer-scale oil droplets that effectively dissolve in water (nano emulsions) to provide optimized bio availability for absorption.
New Video Demonstrates PBIO's Ultra Shear Technology and Potential Impact in CBD, Nutraceuticals, Foods, Cosmetics, and Other Oil-Based Markets
Last Wednesday, the Company released a short video demonstrating the their proprietary Ultra Shear Technology (USTTM) platform and its ability to create extremely small, nanometer-scale oil droplets that effectively dissolve in water (nanoemulsions) to provide optimized bio availability for absorption.
Dr. Bradford A. Young, Chief Commercial Officer of Pressure BioSciences, explained: ''We have all observed how oil and water do not normally mix or dissolve in each other, and routinely separate after mixing. Even with modern, advanced mixing technologies, oils remain in relatively large drops in water, which are poorly absorbed by the body. PBI's proprietary UST platform employs ultra-high pressure and extreme shearing forces to create very small, nano-scale emulsions (nanoemulsions) of oil droplets in water with vastly improved absorption and stability characteristics."
Bioavailability describes the percentage of and rate at which a substance is absorbed into the bloodstream. Oil-water emulsions of nutraceuticals and supplements present a serious challenge for many oral and transdermal therapies, due to most of the beneficial molecules remaining hidden inside of the oil drops. For CBD products commonly consumed orally - including CBD oils in edibles and beverages - absorption is typically below 10% (ERTH 8/28/2018: Water Soluble CBD - The Science of Nanoemulsion and Bioavailability). PBI believes that processing with the UST platform will deliver greatly improved absorption results (90% or higher) for CBD and other oil-based supplements.
Dr. Young continued: ''For many oil-based products, the ability to create nanoemulsions can improve a product's absorption, medicinal benefits, visual appearance, and sensory presentation. The potential for the UST platform to impact the CBD industry is promising, with the total cannabinoid market expected to hit $22 billion by 2022 (Brightfield Group, 2018), with CBD oil-based supplements being the cornerstone of this market. More importantly, while CBD is an attractive opportunity for our proprietary UST platform, we believe that the nutraceuticals, topicals and cosmetics, and food and beverage markets as mentioned could be 10-50 times larger. We will be addressing these additional market opportunities in parallel with our efforts in CBD.''
The short video released today is the first in a series of product-targeted video presentations designed to offer investors, future clients, and other interested groups additional information on PBI's UST platform and the numerous applications and opportunities for this transformational, proprietary technology.
The Company’s President and CEO, Mr. Richard T. Schumacher, recently joined Stock Day’s Mr. Everett Jolly to discuss the Company's most recent developments.
During the interview Mr. Schumacher discussed the following:
PBIO's recent collaboration With Nutra Fuels, Inc.,
The Commercial Launch of Their Bio Pharmaceuticals Contract Services Business.
The Publication of More Than Twenty Scientific Papers on the Company’s Unique Pressure-Based Products During 2018.
Please click here to listen to the full interview.
Technical Analysis:
As we stated before, PBIO appears to be a clear cut winner from a technical standpoint.
Regardless of its recent run-up, we still believe that PBIO has plenty of room to run from here.
The Company is still down thirty-nine percent from its 52-week high of $5.00.
A run back to that high would show traders over +63% in pure profit from today's alert price.
Let's also not forget that the float for PBIO is ridiculously thin at just 1.65 M.
With a float that tight, PBIO has the potential to break out for significant gains in a very short amount of time.
We already witnessed this just a few days ago, when shares of PBIO shot up over +51% in just one session.
We ask that you read up on all of PBIO's most recent news here, and add it to the top of your watch list!
Best Regards,
The TopMarket.Gainers Team
Don't Miss Our Next Huge Winner...
Text 'GAINS' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.
Msg&data rates may apply.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStoc.kLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intra.day data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here.within, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated ten thousand dollars by the Financial Marketing Group to conduct investor relations advertising and marketing for PBIO. We have previously been compensated ten thousand dollars by the Financial Marketing Group to conduct investor relations advertising and marketing for PBIO -which has expired. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
PBIO (Pressure Bio Sciences Inc.)
Current Price: $3.05
Investor Presentation
Chart Analysis
Website | Recent News
========================
Members,
We hope you are enjoying this long weekend, and much deserved time off.
As many of you know, we are coming off an amazing week of trading, which included over +182% in realistic gains.
One company that made a major contribution to that impressive gains totals was PBIO (Pressure Bio Sciences Inc.).
We first brought PBIO to your attention last Wednesday, and watched it deliver over +51% in realistic gains in just one trading session.
We continue to love the growth potential of this highly innovative company.
Based on our chart analysis and current market conditions, we still believe that PBIO has plenty of room to run from here, and should remain on the very top of your watchlist.
About Pressure BioSciences, Inc.
Pressure Bio Sciences, Inc. (PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Their products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or "PCT") hydro static pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydro static pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, bio molecule extraction). Their primary focus is in the development of high pressure-based products for bio marker and target discovery, drug design and development, bio therapeutics characterization and quality control, food science, soil & plant biology, forensics, and counter-bio terror applications. Additionally, PBIO is actively expanding the use of their pressure-based technologies in the following areas: (1) the use of their recently acquired technology from BaroFold, Inc. (the "Baro fold" technology) to allow entry into the biologics manufacturing and contract research services sector, and (2) the use of their recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology ("UST") platform to (i) create stable nano emulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
Investment Highlights
Seasoned Management Team & Board of Directors
Annual Revenue of $2.24M (FY2017)
Three Novel, Enabling, Patent Protected, Proprietary Pressure-based Platforms
Proven Core Technology (Over 300 PCT Systems Installed): Razor/Razor blade Business Model
Sales into the Research Market (fast market penetration with minimal approvals required)
Increasing Number of 3rd Party Publications from Marquee Laboratories
PCT Breaks Through Bottlenecks and Barriers to Enable and Accelerate Scientific Discovery
PreEMT Can Impact and Improve Protein Drug Therapeutics
UST Offers the Potential to Produce Highly Stable Nano emulsions, Including in the Food and CBD Markets
Significant Multi-Billion Dollar Market Opportunity (~500K Scientists in 80K Labs Worldwide)
Company Overview
Three Business Segments - Three Unique Technology Platforms
Research Products and Services (PCT Platform)
PCT: Pressure Cycling Technology (alternating cycles of high/low pressure to control biomolecules)
Focus: to improve the quality of biological sample preparation, one of the most crucial yet errorprone steps in all of scientific research, performed by tens of thousands of scientists worldwide in pharma, biotech, academia and government research laboratories.
15 Patents, 300 PCT Systems installed, 175+ customers, 120+ publications, 2017 revenue ($2.24M)
Biological Contract Services (PreEMT Platform)
PreEMT: Pressure Enabled Protein Manufacturing Technology
Focus: to improve the quality of protein therapeutics, accelerate therapeutic protein development, and manufacture follow-on biologics by employing high pressure for dis aggregation & controlled refolding of re combinant proteins into their native structures for desired drug activity.
8 Patents, Dec 2017 BaroFold Acquisition, Initial Contract Underway, Negotiating with Client #2
Nanoemulsion Manufacturing Services (UST Platform)
UST: Ultra Shear Technology (combines high hydro static pressure & intense shear forces)
Focus: to produce higher quality, more stable nano emulsions with improved absorption, higher bio availability, and lower surfactant levels: food, pharmaceuticals, nutra ceuticals, cosmetics, lubricants, paint, and cannabis oil extracts (water soluble CBD) compared to standard emulsions
Short-Term Growth Drivers
Research Products & Services PCT Platform):
New Next Generation Barocycler 2320EXTREME
Additions to Sales & Marketing Team (one to four field sales managers in 2018)
Novel Micro-Pestle Consumable…Potential Use in Pathology, etc.
Four Additional PCT-based Instruments to be Released over Next 12 Months
PBI Products Fill Existing Needs in $291B (2021 est.) Bio pharmaceutical Market
Biological Contract Services (PreEMT Platform): Consistent Revenue Stream fromServices to Protein Therapeutic Companies…plus the Potential for Millions of dollars from Royalties on Manufacturing Scale Licenses
Nano emulsion Manufacturing Services (UST Platform): Consistent Revenue Stream from Services to Food, Cosmetic, and Nutraceutical (CBD, CBG) Markets for Potential Development of Low Cost, Scalable Production of Nano emulsions…plus the Potential for Millions of dollars from Royalties on Manufacturing Scale Licenses
Recent Developments for PBIO
Pressure Bio Sciences Makes CBD Oil Water Soluble, Offering Solution to CBD Absorption Issue in Food & Beverages
Last week, the Company released a short video demonstrating the Company's proprietary Ultra Shear Technology (USTTM) platform and its ability to create extremely small, nanometer-scale oil droplets that effectively dissolve in water (nano emulsions) to provide optimized bio availability for absorption.
New Video Demonstrates PBIO's Ultra Shear Technology and Potential Impact in CBD, Nutraceuticals, Foods, Cosmetics, and Other Oil-Based Markets
Last Wednesday, the Company released a short video demonstrating the their proprietary Ultra Shear Technology (USTTM) platform and its ability to create extremely small, nanometer-scale oil droplets that effectively dissolve in water (nanoemulsions) to provide optimized bio availability for absorption.
Dr. Bradford A. Young, Chief Commercial Officer of Pressure BioSciences, explained: ''We have all observed how oil and water do not normally mix or dissolve in each other, and routinely separate after mixing. Even with modern, advanced mixing technologies, oils remain in relatively large drops in water, which are poorly absorbed by the body. PBI's proprietary UST platform employs ultra-high pressure and extreme shearing forces to create very small, nano-scale emulsions (nanoemulsions) of oil droplets in water with vastly improved absorption and stability characteristics."
Bioavailability describes the percentage of and rate at which a substance is absorbed into the bloodstream. Oil-water emulsions of nutraceuticals and supplements present a serious challenge for many oral and transdermal therapies, due to most of the beneficial molecules remaining hidden inside of the oil drops. For CBD products commonly consumed orally - including CBD oils in edibles and beverages - absorption is typically below 10% (ERTH 8/28/2018: Water Soluble CBD - The Science of Nanoemulsion and Bioavailability). PBI believes that processing with the UST platform will deliver greatly improved absorption results (90% or higher) for CBD and other oil-based supplements.
Dr. Young continued: ''For many oil-based products, the ability to create nanoemulsions can improve a product's absorption, medicinal benefits, visual appearance, and sensory presentation. The potential for the UST platform to impact the CBD industry is promising, with the total cannabinoid market expected to hit $22 billion by 2022 (Brightfield Group, 2018), with CBD oil-based supplements being the cornerstone of this market. More importantly, while CBD is an attractive opportunity for our proprietary UST platform, we believe that the nutraceuticals, topicals and cosmetics, and food and beverage markets as mentioned could be 10-50 times larger. We will be addressing these additional market opportunities in parallel with our efforts in CBD.''
The short video released today is the first in a series of product-targeted video presentations designed to offer investors, future clients, and other interested groups additional information on PBI's UST platform and the numerous applications and opportunities for this transformational, proprietary technology.
The Company’s President and CEO, Mr. Richard T. Schumacher, recently joined Stock Day’s Mr. Everett Jolly to discuss the Company's most recent developments.
During the interview Mr. Schumacher discussed the following:
PBIO's recent collaboration With Nutra Fuels, Inc.,
The Commercial Launch of Their Bio Pharmaceuticals Contract Services Business.
The Publication of More Than Twenty Scientific Papers on the Company’s Unique Pressure-Based Products During 2018.
Please click here to listen to the full interview.
Technical Analysis:
As we stated before, PBIO appears to be a clear cut winner from a technical standpoint.
Regardless of its recent run-up, we still believe that PBIO has plenty of room to run from here.
The Company is still down thirty-nine percent from its 52-week high of $5.00.
A run back to that high would show traders over +63% in pure profit from today's alert price.
Let's also not forget that the float for PBIO is ridiculously thin at just 1.65 M.
With a float that tight, PBIO has the potential to break out for significant gains in a very short amount of time.
We already witnessed this just a few days ago, when shares of PBIO shot up over +51% in just one session.
We ask that you read up on all of PBIO's most recent news here, and add it to the top of your watch list!
Best Regards,
The TopMarket.Gainers Team
Don't Miss Our Next Huge Winner...
Text 'GAINS' to '67076'
to have our Trade Alerts
Delivered Direct
to your Cell Phone.
(There is no charge.
Msg&data rates may apply.)
DISCLAIMER
This newsletter is a paid advertisement, not a recommendation nor an offer to buy or sell securities. This newsletter is owned, operated and edited by both MJ Capital, LLC and PennyStockLocks, LLC. Any wording found in this e-mail or disclaimer referencing to “I” or “we” or “our” refers to MJ Capital, LLC and PennyStoc.kLocks, LLC. Our business model is to be financially compensated to market and promote small public companies. By reading our newsletter and our website you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature, and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis of making investment decisions, and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our newsletters or on our website.
We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website and newsletter are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our newsletter and on our website may be based on end-of-day or intra.day data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. MJ Capital does NOT own any shares of the companies mentioned here.within, nor intends to buy any in the future.
MJ Capital’s business model is to receive financial compensation to promote public companies. We have been compensated ten thousand dollars by the Financial Marketing Group to conduct investor relations advertising and marketing for PBIO. We have previously been compensated ten thousand dollars by the Financial Marketing Group to conduct investor relations advertising and marketing for PBIO -which has expired. Any compensation is a major conflict of interest in our ability to be unbiased. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. The investor relations marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur. Our emails may contain forward looking statements, which are not guaranteed to materialize due to a variety of factors.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our email newsletters and on our website is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, MJ Capital often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.